BRAF and melanoma: BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) consitute a pharmacological combination that has received approval from the Food and Drug Administration (FDA) for the treatment of patients diagnosed with BRAF-mutated melanoma.